NASDAQ: VBIO
Valion Bio, Inc.CIK 0001787740 · Electromedical Equipment
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade VBIO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Valion Bio shareholders approve 2.6M share equity plan expansion and multiple dilutive financings
5 material changes detected. Sign up free to read the summary.
Valion Bio reports Q1 2026 financial results in routine earnings disclosure
2 material changes detected. Sign up free to read the summary.
No material changes vs prior filing
0 material changes detected. Sign up free to read the summary.
Valion Bio hires Melinda Lackey as General Counsel with $321K salary and 45K options
3 material changes detected. Sign up free to read the summary.
Tivic Health Systems changes name to Valion Bio, ticker to VBIO effective April 28
3 material changes detected. Sign up free to read the summary.
Valion Bio exits ClearUP device business, acquires CDMO assets; losses jump 56% to $8.9M
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 14, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 0.07 | |
| Cost of revenue / cost of sales | 0.02 | |
| Gross profit | 0.05 | |
| Operating expenses: | ||
| Sales and marketing | 0.2 | |
| Research and development | 1.9 | 0.3 |
| General and administrative | 1.0 | |
| Selling, general and administrative | 3.8 | 1.0 |
| Total operating expenses | 5.6 | 1.4 |
| Operating income | (5.6) | (1.4) |
| Interest expense | 0.6 | — |
| Other income/(expense), net | (0.6) | — |
| Net income | (6.2) | (1.5) |
| Basic earnings per share | (2.23) | (2.52) |
| Diluted earnings per share | (2.52) | |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 7.2 | 0.7 |
| Accounts receivable, net | 0.01 | |
| Inventories | 0.8 | 0.3 |
| Prepaid expenses and other current assets | 0.7 | 0.3 |
| Total current assets | 8.7 | 1.3 |
| Property, plant and equipment, net | 12.6 | 0.1 |
| Operating lease right-of-use assets, net | 10.1 | |
| Identifiable intangible assets, net | 2.2 | |
| Goodwill | 3.5 | |
| Deferred income taxes and other assets | 0.2 | — |
| Other long-term assets | 0.9 | 2.4 |
| TOTAL ASSETS | 38.2 | 3.8 |
| Current liabilities: | ||
| Accounts payable | 0.6 | 0.4 |
| Current portion of operating lease liabilities | 0.5 | |
| Income taxes payable | 0.05 | 0.05 |
| Other current liabilities | 1.4 | 0.3 |
| Total current liabilities | 2.6 | 0.7 |
| Operating lease liabilities | 9.6 | |
| Deferred income taxes and other liabilities | 0.3 | |
| Other long-term liabilities | 7.2 | — |
| Total liabilities | 19.7 | 0.7 |
| Shareholders' equity: | ||
| Common stock | — | — |
| Capital in excess of stated value | 70.1 | 48.1 |
| Retained earnings (deficit) | (59.0) | (45.0) |
| Total shareholders' equity | 11.1 | 3.0 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 38.2 | 3.8 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (5.0) | (0.9) |
| Investing Activities: | ||
| Net cash from investing activities | (0.01) | (0.5) |
| Financing Activities: | ||
| Net cash from financing activities | (0.04) | 0.08 |
| Net increase/(decrease) in cash | (5.1) | (1.3) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗